Technical Analysis for VERU - Veru Inc.

Grade Last Price % Change Price Change
D 0.57 -2.14% -0.01
VERU closed down 2.14 percent on Monday, March 18, 2024, on 32 percent of normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Fell Below 20 DMA Bearish -2.14%
MACD Bearish Signal Line Cross Bearish -2.14%
1,2,3 Pullback Bullish Bullish Swing Setup -2.14%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.14%
Wide Bands Range Expansion -2.14%
Wide Bands Range Expansion -5.42%
Gapped Up Strength -5.42%

   Recent Intraday Alerts

Alert Time
Down 5% about 16 hours ago
Gap Up Closed about 16 hours ago
Down 3% about 16 hours ago
Fell Below Previous Day's Low about 16 hours ago
Down 2 % about 16 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Veru Inc. Description

Veru Inc., a medical therapeutics company, develops, manufactures, and markets consumer health care products. The company’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus. The company primarily serves global agencies, non-government organizations, ministries of health, and other governmental agencies directly, as well as through distribution agreements and other arrangements with commercial partners. It has operations in the United States, Brazil, Zimbabwe, South Africa, Angola, the Democratic Republic of the Congo, Tanzania, Malaysia, Spain, France, the United Kingdom, and internationally. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Organic Compounds Chemical Compounds Infection Chemotherapy Prostate Cancer Flash Ovarian Cancer Dysfunction Fertility Health Care Products Fever HIV/Aids Benign Prostatic Hyperplasia Hyperplasia Infertility Consumer Health Care Consumer Health Care Products Gout Hot Flash Zika Male Infertility Treatment Of Benign Prostatic Hyperplasia

Is VERU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.75
52 Week Low 0.36
Average Volume 1,933,298
200-Day Moving Average 0.88
50-Day Moving Average 0.51
20-Day Moving Average 0.60
10-Day Moving Average 0.62
Average True Range 0.06
RSI (14) 48.45
ADX 34.06
+DI 22.08
-DI 19.45
Chandelier Exit (Long, 3 ATRs) 0.55
Chandelier Exit (Short, 3 ATRs) 0.57
Upper Bollinger Bands 0.69
Lower Bollinger Band 0.51
Percent B (%b) 0.32
BandWidth 30.20
MACD Line 0.02
MACD Signal Line 0.03
MACD Histogram -0.0064
Fundamentals Value
Market Cap 83.09 Million
Num Shares 146 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -0.52
Price-to-Sales 3.85
Price-to-Book 3.06
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.66
Resistance 3 (R3) 0.66 0.63 0.64
Resistance 2 (R2) 0.63 0.61 0.63 0.64
Resistance 1 (R1) 0.60 0.59 0.58 0.60 0.63
Pivot Point 0.57 0.57 0.56 0.57 0.57
Support 1 (S1) 0.54 0.55 0.52 0.54 0.50
Support 2 (S2) 0.51 0.53 0.51 0.50
Support 3 (S3) 0.48 0.51 0.49
Support 4 (S4) 0.48